Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ivivi Looks To Ease Post-Surgery Pain, Turn Profit With Help From Allergan

This article was originally published in The Gray Sheet

Executive Summary

Electromagnetic pain control device maker Ivivi Technologies is looking to leverage a new marketing partnership strategy along with new data and clinical guidelines to help lift its business into profitability

You may also be interested in...



People In Brief

Coapt Systems: Silicon Valley aesthetics firm appoints Laureen DeBueno as president and CEO Aug. 1. DeBueno has more than 25 years management experience in the medical device and technology markets, most recently as chief financial officer of Thermage. Coapt makes bioabsorbable implants for the fixation of soft tissue in the plastic, reconstructive and sports medicine markets

People In Brief

Coapt Systems: Silicon Valley aesthetics firm appoints Laureen DeBueno as president and CEO Aug. 1. DeBueno has more than 25 years management experience in the medical device and technology markets, most recently as chief financial officer of Thermage. Coapt makes bioabsorbable implants for the fixation of soft tissue in the plastic, reconstructive and sports medicine markets

Financings In Brief

Home Diagnostics, Inc. goes public: Blood glucose monitor firm goes public Sept. 20 via a $79 mil. offering of about 6.6 mil. common stock shares at $12 each. The Fort Lauderdale, Fla., firm will use the proceeds to buy manufacturing equipment, repay debt and redeem preferred stock. R&D projects include low-cost biosensors, on-strip coding technology and wireless connectivity enhancements. Current offerings, based on both photometric and biosensor technology, include the firm's SideKick disposable blood glucose testing system and the Prestige IQ, TrueTrack Smart and TrackEase Smart advanced systems. HDI, which generated 2005 sales of $100 mil. (up 18% for the year) and is profitable, competes with larger firms including Johnson & Johnson, Roche, Abbott, Bayer and BD, primarily by offering low-cost systems using comparable technology. The company trades under the Nasdaq symbol "HDIX"...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024873

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel